Lack of CD8+ tumor-infiltrating lymphocytes, low PD-1 expression, and tumor mutation burden factors are thought to be the primary influencing factors leading to insensitivity to immunotherapy in advanced breast cancer. The gene discussed is CD8A; the disease is neoplasm.